Literature DB >> 11983687

Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420.

Tri-Hung Nguyen1, Jian Liu, Paul J Lombroso.   

Abstract

A family of protein tyrosine phosphatases enriched within the central nervous system called striatal enriched phosphatase (STEP) has been implicated in the regulation of the N-methyl-d-aspartate receptor. STEP(61), a membrane-associated isoform located in the postsynaptic densities (PSDs) of striatal neurons, contains two transmembrane domains, two proline-rich domains, and a kinase-interacting motif. This study demonstrates that STEP(61) associates with Fyn, a member of the Src family kinases that is also enriched in PSDs. By using human embryonic kidney 293 cells for co-transfection, we determined that a substrate-trapping variant (STEP(61) CS) binds to Fyn but not to other members of the Src family present in PSDs. In a complementary experiment, myc-tagged Fyn immunoprecipitates STEP(61) CS. STEP(61) binds to Fyn through one of its proline-rich domains and the kinase-interacting motif domain, whereas Fyn binds to STEP(61) through its Src homology 2 domain and the unique N-terminal domain. STEP(61) CS pulls down Fyn when the Tyr(420) site is phosphorylated. In vitro, wild-type STEP(61) dephosphorylates Fyn at Tyr(420) but not at Tyr(531). These results suggest that STEP regulates the activity of Fyn by specifically dephosphorylating the regulatory Tyr(420) and may be one mechanism by which Fyn activity is decreased within PSDs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11983687     DOI: 10.1074/jbc.M111683200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  89 in total

1.  Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents.

Authors:  Juan José Muñoz; Céline Tárrega; Carmen Blanco-Aparicio; Rafael Pulido
Journal:  Biochem J       Date:  2003-05-15       Impact factor: 3.857

2.  Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.

Authors:  Ana Saavedra; Albert Giralt; Laura Rué; Xavier Xifró; Jian Xu; Zaira Ortega; José J Lucas; Paul J Lombroso; Jordi Alberch; Esther Pérez-Navarro
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

3.  Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.

Authors:  S M Goebel-Goody; E D Wilson-Wallis; S Royston; S M Tagliatela; J R Naegele; P J Lombroso
Journal:  Genes Brain Behav       Date:  2012-04-06       Impact factor: 3.449

4.  In vitro stretch injury induces time- and severity-dependent alterations of STEP phosphorylation and proteolysis in neurons.

Authors:  Mahlet N Mesfin; Catherine R von Reyn; Rosalind E Mott; Mary E Putt; David F Meaney
Journal:  J Neurotrauma       Date:  2012-06-25       Impact factor: 5.269

5.  Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61.

Authors:  Pradeep Kurup; Yongfang Zhang; Jian Xu; Deepa V Venkitaramani; Vahram Haroutunian; Paul Greengard; Angus C Nairn; Paul J Lombroso
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

6.  Oxidative stress-induced oligomerization inhibits the activity of the non-receptor tyrosine phosphatase STEP61.

Authors:  Ishani Deb; Ranjana Poddar; Surojit Paul
Journal:  J Neurochem       Date:  2011-01-19       Impact factor: 5.372

7.  Down-regulation of BDNF in cell and animal models increases striatal-enriched protein tyrosine phosphatase 61 (STEP61 ) levels.

Authors:  Jian Xu; Pradeep Kurup; Garikoitz Azkona; Tyler D Baguley; Ana Saavedra; Angus C Nairn; Jonathan A Ellman; Esther Pérez-Navarro; Paul J Lombroso
Journal:  J Neurochem       Date:  2015-09-17       Impact factor: 5.372

8.  A peptide mimetic of tyrosine phosphatase STEP as a potential therapeutic agent for treatment of cerebral ischemic stroke.

Authors:  Ranjana Poddar; Sathyanarayanan Rajagopal; Lucas Winter; Andrea M Allan; Surojit Paul
Journal:  J Cereb Blood Flow Metab       Date:  2017-12-07       Impact factor: 6.200

9.  Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.

Authors:  Clare M Gladding; Jing Fan; Lily Y J Zhang; Liang Wang; Jian Xu; Edward H Y Li; Paul J Lombroso; Lynn A Raymond
Journal:  J Neurochem       Date:  2014-04-02       Impact factor: 5.372

10.  Inhibition of striatal-enriched tyrosine phosphatase 61 in the dorsomedial striatum is sufficient to increased ethanol consumption.

Authors:  Emmanuel Darcq; Sami Ben Hamida; Su Wu; Khanky Phamluong; Viktor Kharazia; Jian Xu; Paul Lombroso; Dorit Ron
Journal:  J Neurochem       Date:  2014-03-27       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.